(Q28214785)

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Hepatitis B vaccination and the risk of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The genetic epidemiology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A meta-analysis of genomic screens in multiple sclerosis. The Transatlantic Multiple Sclerosis Genetics Cooperative

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Changed distribution of sodium channels along demyelinated axons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Electrically active axons degenerate when exposed to nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Axonal loss in normal-appearing white matter in a patient with acute MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Transcallosal bands: a sign of neuronal tract degeneration in early MS?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Beta-interferon and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

New treatments and azathioprine in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Anergy induction by dimeric TCR ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

The restoration of conduction by central remyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Continuing optic nerve atrophy following optic neuritis: a serial MRI study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908220-X

7 January 2021

10.1016/S0140-6736(02)08220-X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

11955556

1 reference

Consolidated OpenCitations Corpus – April 2017